LONDON, October 17, 2014 /PRNewswire/ --
Investor-Edge has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), NPS Pharmaceuticals Inc. (NASDAQ: NPSP), XOMA Corporation (NASDAQ: XOMA), Momenta Pharmaceuticals Inc. (NASDAQ: MNTA), and Catalyst Pharmaceutical Partners Inc. (NASDAQ: CPRX). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Thursday, October 16, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 16,117.24, down 0.15% and the NASDAQ Composite closed at 4,217.39, up 0.05%. The S&P 500 finished the session 0.01% higher at 1,862.76. During the trading session, five out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 696.64, down 0.50%, whereas the index has advanced 8.46% on YTD basis. Register for your complimentary reports on these five stocks at:
http://investor-edge.com/register
On Thursday, Arena Pharmaceuticals Inc.'s stock rallied 5.48%, to close the day at $4.04. The stock recorded a trading volume of 6.56 million shares, above its three months average volume of 4.65 million shares. The company's shares oscillated between $3.75 and $4.13 during the session. Over the last three trading sessions and over the past one month, Arena Pharmaceuticals Inc.'s shares have gained 14.45% and 3.06%, respectively. However, the stock has lost 30.94% since the start of this year. The stock is trading below its 50-day and 200-day moving averages. Arena Pharmaceuticals Inc.'s 200-day moving average of $5.68 is above its 50-day moving average of $4.09. Additionally, the stock has a Relative Strength Index (RSI) of 44.11. Sign up and read the free notes on ARNA at:
www.Investor-Edge.com/ARNA-17Oct2014
On Thursday, shares in NPS Pharmaceuticals Inc. recorded a trading volume of 2.45 million shares, higher than its three months average volume of 1.99 million shares. The stock ended the day at $26.42, which was 5.98% above its previous day's closing of $24.93, and registered an intraday range of $24.22 and $26.66. Shares of the company traded at a PE ratio of 1603.45. Although NPS Pharmaceuticals Inc.'s stock has surged 13.59% in the previous three trading sessions, it has fallen by 2.65% in the last one month and 12.98% on YTD basis respectively. The stock is trading below its 50-day and 200-day moving averages of $27.17 and $30.27, respectively. Furthermore, shares of NPS Pharmaceuticals Inc. have an RSI of 46.91. The complimentary notes on NPSP can be downloaded as in PDF format at:
www.Investor-Edge.com/NPSP-17Oct2014
XOMA Corp.'s stock surged 3.30% to end Thursday's session at $4.07. The stock recorded a trading volume of 2.03 million shares, above its three months average volume of 1.31 million shares. The company's shares fluctuated between $3.77 and $4.11 during the session. XOMA Corp.'s shares have declined 39.52% since the beginning of 2014. However, the stock has gained 7.67% over the previous three trading sessions and 4.09% in the last three months. The stock is trading below its 50-day and 200-day moving averages. XOMA Corp.'s 200-day moving average of $5.19 is above its 50-day moving average of $4.27. Additionally, the stock has an RSI of 43.11. Register for free on Investor-Edge and access the latest research on XOMA at:
www.Investor-Edge.com/XOMA-17Oct2014
On Thursday, shares in Momenta Pharmaceuticals Inc. fluctuated between $10.40 and $11.48 before ending the session 5.31% higher at $11.31. The stock reported a trading volume of 0.67 million shares, higher than its three months average volume of 0.44 million shares. Momenta Pharmaceuticals Inc.'s shares have advanced 14.24% in the previous three trading sessions and 2.08% in the last one month, while the stock has declined 36.03% on YTD basis. The stock is trading below its 50-day and 200-day moving averages of $11.47 and $13.25, respectively. Moreover, shares of Momenta Pharmaceuticals Inc. have an RSI of 43.71. The complete research on MNTA is available for free at:
www.Investor-Edge.com/MNTA-17Oct2014
Shares in Catalyst Pharmaceutical Partners Inc. finished Thursday's session 0.41% lower at $2.43. A total of 0.72 million shares were traded, which was below its three months average volume of 1.32 million shares. The stock vacillated between $2.31 and $2.53 during the session. Over the previous three trading sessions and last one month, Catalyst Pharmaceutical Partners Inc.'s shares have lost 2.41% and 22.86%, respectively. However, from the beginning of 2014, the stock has gained an upside of 24.62%. The company's shares are trading above their 200-day moving average. Moreover, the stock's 50-day moving average of $2.77 is greater than its 200-day moving average of $2.30. Catalyst Pharmaceutical Partners Inc.'s stock has an RSI of 39.27. Free in depth research on CPRX is available at:
www.Investor-Edge.com/CPRX-17Oct2014
About Investor-Edge.com
At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.investor-edge.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Investor-Edge
